PMD-026 is under clinical development by Phoenix Molecular Designs and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PMD-026’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PMD-026 overview
PMD-026 is under development for the treatment of triple-negative breast cancer, metastatic breast cancer, ER positive human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), colorectal cancer, lung cancer, melanoma, prostate cancer, hematopoietic cancers including myelofibrosis and acute myeloid leukemia. It is a small molecule administered through oral route. The drug candidate acts by targeting ribosomal s6 kinases RSK1 and RSK2.
It was under development for the treatment of castration-resistant prostate cancer.
Phoenix Molecular Designs overview
Phoenix Molecular Designs (PhoenixMD) is a pharmaceutical company developing drugs for the treatment of various cancers. Its pipeline products include PMD-026 for solid tumors, hematopoietic cancers like myelofibrosis and acute myeloid leukemia. The company’s lead pipeline product in combination with fulvestrant, selective estrogen receptor inhibitors and orserdu used for the treatment of breast cancer. It acts by inhibiting the ribosomal kinase enzyme (RSK inhibitors) and prevents cancer cell growth. The company operates in the US and Canada. PhoenixMD is headquartered in Vancouver, British Columbia, Canada.
For a complete picture of PMD-026’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
